Mainz Biomed B.V.
MYNZ
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-onlyā¦ read more
Healthcare
Diagnostics & Research
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.18
Price-6.75%
-$0.08
1Y
Price
Market Cap
$4.808m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-2700.7%
EBITDA Margin-2910.2%
Net Profit Margin-2273.0%
Free Cash Flow Margin-2700.7%
EBITDA Margin-2910.2%
Net Profit Margin-2273.0%
Free Cash Flow MarginRevenue
$1.395m
+56.1%
1y CAGR+41.6%
3y CAGR+29.2%
5y CAGREarnings
-$35.178m
-62.5%
1y CAGR-14.7%
3y CAGR-42.6%
5y CAGREPS
-$41.82
-87.0%
1y CAGR-451.3%
3y CAGR-341.5%
5y CAGRBook Value
$2.522m
$9.804m
Assets$7.281m
Liabilities$3.094m
DebtDebt to Assets
31.6%
-0.1x
Debt to EBITDAFree Cash Flow
-$28.779m
-65.9%
1y CAGR-31.1%
3y CAGR-117.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company